Recursion Pharmaceuticals Inc (RXRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.99B
Last updated: Nov 17, 2026 at 4:44 PM ET
Recursion Pharmaceuticals Inc (RXRX) Statistics
Recursion Pharmaceuticals (RXRX) has a market cap of $1.99B and an enterprise value of $1.45B. It kept -697.13% of revenue as net income over the last 12 months. Its share count is up 21.48% from a year earlier.
Total Valuation
Enterprise value is 27.10% below the market cap, as cash exceeds debt.
| Market Cap | $1.99B |
|---|---|
| Enterprise Value | $1.45B |
| Latest price (Nov 17, 2026) | $2.72 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 21.6x and 1.6x. Its year-end P/S ranged from 25.3x to 107.3x from 2021 to 2025.
| P/S Ratio | 21.6x |
|---|---|
| Forward P/S | 49.1x |
| P/B Ratio | 1.6x |
| P/TBV Ratio | 3.1x |
Price Statistics
The stock is down 34.30% over 52 weeks and trades 27.47% below its 50-day average.
| Beta (1Y) | 2.94 |
|---|---|
| 52-Week Change | -34.30% |
| 1-Month Change | -24.65% |
| 3-Month Change | -22.29% |
| 6-Month Change | -4.56% |
| 5-Year Change | -78.96% |
| Total Return (1Y) | -34.30% |
| Total Return (3Y CAGR) | -27.20% |
| Total Return (5Y CAGR) | -32.39% |
| Return vs SPY (1Y) | -46.17% |
| Max Drawdown (1Y) | -45.16% |
| Max Drawdown (3Y) | -82.47% |
| Sharpe Ratio (1Y) | -0.57 |
| Correlation with SPY (1Y) | 0.54 |
| 50-Day Average | $3.75 |
| 200-Day Average | $3.46 |
| 52-Week Range | $2.77 to $5.24 |
| RSI (14 Days) | 33.3 |
| Average Volume (20 Days) | 21.35M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.01x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 5.01x |
|---|---|
| Quick Ratio | 5.01x |
| Debt / Equity | 0.01x |
Returns and Efficiency
Return on invested capital is -51.83% over the last 12 months, against a 5-year average of -47.27%.
| Return on Equity (ROE) | -52.51% |
|---|---|
| Return on Assets (ROA) | -38.93% |
| Return on Invested Capital (ROIC) | -51.83% |
| Return on Capital Employed (ROCE) | -43.71% |
| ROE (5Y Average) | -51.25% |
| ROA (5Y Average) | -38.13% |
| ROIC (5Y Average) | -47.27% |
| Asset Turnover | 0.05x |
| Receivables Turnover | 2.82x |
Scores
RXRX has an Altman Z-Score of -0.75, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.75 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $68.23M over the last 12 months is up 56.18% from the 12 months before.
| Revenue | $68.23M |
|---|---|
| Revenue Growth (YoY) | +56.18% |
| Gross Profit | $19.93M |
| Operating Income | -$494.98M |
| Pretax Income | -$480.23M |
| Net Income | -$475.67M |
| EBITDA | -$406.38M |
| EBIT | -$480.23M |
| Reported EPS (TTM) | -$0.90 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 74.25% of the $1.22B in total assets.
| Cash and Equivalents | $549.85M |
|---|---|
| Total Debt | $11.90M |
| Net Cash | $537.95M |
| Net Cash Per Share | $0.99 |
| Working Capital | $493.10M |
| Shareholder Equity | $905.81M |
| Book Value Per Share | $1.67 |
| Tangible Book Value | $471.43M |
| Tangible Book Per Share | $0.87 |
| Total Assets | $1.22B |
| Total Liabilities | $315.90M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.95M of capital spending, operating cash flow left -$312.48M of free cash flow.
| Operating Cash Flow | -$310.53M |
|---|---|
| Capital Expenditures | $1.95M |
| Free Cash Flow | -$312.48M |
| FCF Per Share | -$0.52 |
| Depreciation and Amortization | $73.85M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -725.44%.
| Gross Margin | 29.21% |
|---|---|
| Operating Margin | -725.44% |
| Pretax Margin | -703.82% |
| Net Margin | -697.13% |
| EBITDA Margin | -595.58% |
| EBIT Margin | -703.82% |
| FCF Margin | -457.97% |
| Gross Margin (5Y Average) | 22.28% |
Growth
Revenue grew 23.30% a year over 3 years.
| Revenue Growth (3Y CAGR) | +23.30% |
|---|---|
| Revenue Growth (5Y CAGR) | +79.91% |
| Book Value Per Share Growth (2Y CAGR) | +3.93% |
| Tangible Book Per Share Growth (2Y CAGR) | -11.81% |
Dividends and Yields
RXRX does not pay a dividend. Its free cash flow yield is -21.16%.
| FCF Yield | -21.16% |
|---|---|
| Buyback Yield | -14.87% |
| Shareholder Yield | -14.87% |
Peer Position
Against 9 similar companies, RXRX has the 3rd highest P/S.
P/S RatioPeer median 5.2x
ROICPeer median -47.54%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +49.45%
| P/S Ratio | 21.6x vs 5.2x median |
|---|---|
| ROIC | -51.83% vs -47.54% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +56.18% vs +49.45% median |
Analyst Forecast
Consensus estimates put revenue growth at -23.05% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -23.05% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RXRX
What is RXRX's market cap?
Recursion Pharmaceuticals has a market cap of $1.99B. Its enterprise value, which adds debt and subtracts cash, is $1.45B.
How many shares of RXRX are outstanding?
Recursion Pharmaceuticals has 543.00M shares outstanding. The count is up 21.48% from a year earlier.
Does RXRX pay a dividend?
No. Recursion Pharmaceuticals does not pay a dividend.
How much debt does RXRX have?
Recursion Pharmaceuticals has $11.90M of total debt and $549.85M of cash and equivalents, a net cash position of $537.95M.
RXRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors